New tools are needed to match pancreatic cancer patients with effective treatments. Patient-derived organoids offer a high-throughput platform to personalize treatments and discover novel therapies.
Introduction
Pancreatic cancer has one of the lowest 5-year survival rates of all cancer types (8%) (1) , and is projected to be the second leading cause of cancer death by 2030 (2) . Surgery is required to cure pancreatic cancer (3) , but can only be performed in 5-10% of cases, and only offers a 10.4% 5-year survival rate (4) .
Chemotherapy can enhance survival after surgery and standard treatments in the adjuvant setting include gemcitabine and gemcitabine combined with capecitabine (5-fluorouracil (5-FU) pro-drug) (5) . Promising treatments for early-stage pancreatic cancer following surgery include gemcitabine combined with nabpaclitaxel, and FOLFIRINOX. Currently, oncologists must weigh these drug treatment options for individual patients based solely on potential side effects and have no a priori indication of whether a pancreatic cancer patient will respond to standard therapies. There is a need for a predictive tool to screen and identify alternative therapies that would benefit individual patients with either resectable or more advanced unresectable pancreatic cancer. Such a tool would minimize the needless costs and side effects accompanying ineffective treatment, while maximizing long-term survival rates. Additionally, the discovery of novel therapies would be accelerated by the ability to rapidly investigate the clinical efficacy of many drug candidates for many patients.
Tailoring treatment based on genomic analysis alone is insufficient due to poor understanding of the connections between pancreatic tumor driver mutations and drug response. Despite being less genetically diverse than most cancers, targeted approaches to treating pancreatic cancer have failed in clinical trials and drug treatment is limited to cytotoxic chemotherapies. Most pancreatic tumors do not express a specific therapeutic target (6) , and the driver mutations present in a patient's cancer do not predict their response to chemotherapy. Alternatively, pancreatic organoids have emerged as an appealing method to tailor treatments by performing high-throughput drug screening directly on a patient's tumor cells (7) (8) (9) . In vitro organoids recapitulate the genetic and histopathological characteristics of the original pancreatic tumor, along with its complex 3-dimensional organization (10) (11) (12) (13) (14) . Organoid cultures also preserve interactions between tumor cells, immune cells (15) , and fibroblasts (16) , which can influence tumor drug response and are potential drug targets (17, 18) . Generally, methods for measuring drug response in organoids have involved either cell viability assays, pooling of proteins, DNA, and RNA from many organoids, or tracking of organoid diameter changes. These methods homogenize the response of an entire organoid or many organoids and ignore cellular heterogeneity, which drives tumor treatment resistance (19) (20) (21) (22) . It is possible that minority subpopulations of lethal drug-resistant cells go completely undetected without more advanced assessment tools. Additionally, these methods generally neglect cellular metabolism, which is a major factor determining cellular drug response and heterogeneity (23) (24) (25) .
Optical metabolic imaging (OMI) is a non-destructive, high-resolution fluorescence microscopy technique that quantifies the metabolic state of individual cells within a single organoid using cellular autofluorescence (26, 27) . The fluorescence properties of NADH and NADPH overlap and are referred to as NAD(P)H. NAD(P)H, an electron donor, and FAD, an electron acceptor, are fluorescent metabolic coenzymes present in all living cells. The optical redox ratio, defined as the ratio of the fluorescence intensity of NAD(P)H to that of FAD, reflects the redox state of the cell (28) (29) (30) , and is sensitive to shifts in metabolic pathways (27, 31, 32) . The fluorescence lifetimes of NAD(P)H and FAD are both twoexponential with distinct lifetimes for the free-and protein-bound conformations, and thus reflect the protein-binding activities of NAD(P)H and FAD (33) (34) (35) . The optical redox ratio, NAD(P)H, and FAD fluorescence lifetimes all provide complimentary information, and can be combined into a composite endpoint called the OMI index (36) . This metric distinguishes drug-resistant and responsive cells by their metabolic states and is robust and sensitive in pancreatic organoids (7) .
OMI of organoids could improve predictions of patient outcomes for several reasons. First, druginduced changes in cell metabolism precede changes in tumor size or overall cell viability (7, 27, 36, 37) , and thus can measure drug response faster than conventional methods such as apoptosis and proliferation assays. Second, OMI analysis of cell subpopulations identifies and quantifies tumor heterogeneity (37, 38) , which is vital to accurately capture patient drug response. Finally, OMI is non-invasive and does not require exogenous labels, so treatment response can be tracked over time in the same organoids. This is not possible with standard techniques which, by necessity, destroy samples. Therefore, OMI provides a fast, dynamic method to evaluate heterogeneous drug response at the organoid and single-cell level, integrating tumor heterogeneity into treatment planning and drug discovery. OMI of organoids has been validated as an accurate predictor of in vivo drug response in mouse models of pancreatic cancer (7), but
has not yet been evaluated in humans. This study is the first to demonstrate that OMI of cellular metabolic heterogeneity in pancreatic tumor organoids provide an early measure of long-term in vivo drug response for individual patients.
Materials and methods
Tissue processing and organoid culture. Human tissue was collected with informed consent from all patients, and all studies were approved by the Institutional Review Board at the University of WisconsinMadison. Surgically resected tissue was placed in cold chelation buffer on ice for one hour. Tissues were washed with PBS and digested at 37°C in DMEM/F12 medium (Invitrogen) containing 1 mg/mL collagenase (Sigma), 0.125 mg/mL dispase (Invitrogen), 10% FBS (Gibco), and 1% pen-strep (Gibco) for 2-3 hours with intermittent shaking. The resulting cell macro-suspension was rinsed in PBS, re-suspended in 1:1 DMEM/F12:Matrigel, plated in 50 μl droplets, and allowed to solidify at 37°C, 5% CO2 in a cell incubator. Once solidified, droplets were overlaid with DMEM/F12 supplemented with 7% FBS, 20 μM Y-27632 (Sigma), 50 ng/ml EGF (Invitrogen), RSPO-conditioned medium (homemade) and 1% penicillin-streptomycin (Gibco). FBS, Y-27632, and RSPO-conditioned medium were removed from cultures if fibroblasts were out-growing tumor cells. Multiphoton imaging. Fluorescence imaging was performed using a custom multiphoton fluorescence lifetime system (Bruker Fluorescence Microscopy). A 40x water immersion objective (Nikon, 1.15 NA) was used with an inverted microscope (Nikon, TiE). A titanium:sapphire laser (Spectra-Physics InSight DS+) was used for excitation, while GaAsP photomultiplier tubes (H7422P-40, Hamamatsu) detected emission light. 750 nm and 890 nm light were used for two-photon excitation of NAD(P)H and FAD, respectively. A 440/80 nm filter was used to collect NAD(P)H fluorescence emission, and a 550/100 nm filter was used to collect FAD fluorescence emission. Images were acquired over 60 seconds, with a pixel dwell time of 4.8 μs for 256x256 pixel images. Fluorescence lifetime data with 256 time bins was acquired using time-correlated single photon counting electronics (SPC-150, Becker & Hickl). A Fluoresbrite YG microsphere (Polysciences) was imaged daily as a fluorescence lifetime standard, which had a stable lifetime (2.09 ± 0.05 ns, n=61), consistent with previously published values (26, 33, 35) .
Organoid imaging. Imaging of organoids was performed in 35 mm glass-bottom dishes (#P35G-1.5-14-C, MatTek). At least five representative organoids were imaged in each treatment group at each time point. At least two additional images of the fibroblast monolayer on the coverslip were taken, if present.
Images were acquired 1, 2, 3, 5, and 7 days after initial treatment.
Cyanide experiment. Four previously untreated organoids from Patient 1 underwent OMI immediately before and after the addition of media containing 12 mM NaCN (Sigma), for a final concentration of 6 mM. OMI endpoints were quantified at the single-cell level, at least 60 cells per group. Redox ratio values were normalized to the pre-treatment average.
Image analysis. NAD(P)H and FAD fluorescence lifetime images were analyzed using SPCImage software (Becker & Hickl) (44) . Briefly, a histogram of photon counts per temporal bin, or decay curve, is generated for each pixel by binning the photon counts of all 9 surrounding pixels. This decay curve is deconvolved with the instrument response function, and then fit to a two-component exponential decay (Equation 1).
Here, ( ) represents the fluorescence intensity measured at time , 1 and 2 represent the fractional contributions of the short and long lifetime components to the overall signal respectively, 1 and 2 are the short and long lifetime components respectively, and represents background light. The two lifetime components are used to distinguish between the free and bound forms of NAD(P)H and FAD (45, 46) . The mean lifetime ( ) is a weighted average of the free and bound lifetimes, and is calculated for both NAD(P)H and FAD in each pixel using Equation 2.
The optical redox ratio was calculated for each pixel by dividing the intensity of NAD(P)H by the intensity of FAD. A customized CellProfiler (v1.0.6025) routine was written to mask individual cell cytoplasms and extract average NAD(P)H and FAD intensities and lifetime components for each cell cytoplasm (47, 48) . All reported redox ratios are normalized to average control values of the same patient and time point.
OMI index calculation. The OMI index, in this study, is a linear combination of three independent OMI endpoints (redox ratio, NAD(P)H , and FAD ), each centered around the average value measured in control cells within each patient at the same experimental time point. This differs from previous descriptions (7, 36) where the end points are mean-centered across all cells in all treatment groups. This modification allows drug responses to be compared between patients in this study. As before, the redox ratio, NAD(P)H , and FAD are given coefficients of (1,1,-1). A decrease in OMI index relative to control correlates with drug response, while an increase or lack of change indicates drug resistance.
Subpopulation analysis.
A Gaussian mixture distribution model was used to assess heterogeneity of cellular metabolism (7, 36, 38, 49) . OMI values for all cells within a treatment group and time point are input into this model described by Equation 3.
Here, represents the number of subpopulations in the model, ( ; , ) is a normal probability density function where represents the mean and represents variance, and is the mixing proportion.
Models containing = 1, 2, and 3 subpopulations are fit to the data, and the goodness of fit for each model is assessed using the Akaike information criterion (AIC) (50) . The best fit of the three models, equivalent to the lowest AIC, is used to evaluate heterogeneity. For comparison, distributions are normalized such that all have an area under the curve of 1. The weighted heterogeneity index (wH-index, Eq. 4) is based on the Gaussian distribution models described by Eq. 3, and is a modified form of the Shannon diversity index used to quantify the degree of heterogeneity (37, 51) .
Here, represents each subpopulation in the Gaussian distribution model, represents the distance between the median of each subpopulation and the median of the entire distribution, represents the proportion of all cells belonging to that subpopulation, and 2 is the variance.
Organoid immunofluorescence. Organoids were rinsed in PBS and fixed for 20 minutes in 4% paraformaldehyde (VWR). Fixed organoids were rinsed and stored in PBS at 4°C until stained. Organoids were blocked for one hour in PBS with 10% goat serum and 0.3% Triton-X 100 (Sigma) at room temperature followed by co-incubation with Ki67 antibody conjugated to AlexaFluor 488 (1:50, Cell
Signaling #11882S) and CC3 antibody conjugated to AlexaFluor 555 (1:50, Cell Signaling #9604S).
Organoids were then washed in PBS and mounted to a slide using ProLong™ Diamond Antifade
Mountant with DAPI (Molecular Probes). DAPI was imaged on the multiphoton microscope at 40x magnification using 750 nm for excitation and 440/80 nm bandpass filter for emission. AlexaFluor 488 was imaged using 965 nm for excitation and 550/100 nm filter for emission. AlexaFluor 555 was imaged Tumor volume was measured with calipers using the formula 0.5*length*width 2 . When average tumor volume reached ~150 mm 3 , mice were randomized into two groups. 20 mice received 100 mg/kg gemcitabine and 100 mg/kg nab-paclitaxel weekly via intraperitoneal injection while 23 control mice received only PBS weekly. Tumor volume was measured twice weekly. Mice were euthanized and tumors were collected when humane endpoints were reached.
High-depth targeted gene sequencing. Patient 13 organoids were sequenced using the Qiagen
Comprehensive Cancer Panel and molecular barcode technology, with greater than 500x median coverage.
UMAP clustering. UMAP (Uniform Manifold Approximation and Projection) was performed on
metabolic imaging data from all organoid cells (control and treated) from all patients and time points (N ~ 45,000) using the UMAP.py package (52) . Nine metabolic measures: redox ratio, NAD(P)H ,
, and FAD 1 were reduced to two components. Points could have 10 neighbors in the manifold structure, and cosine was used to measure distance in the multivariate space. The two resulting components were visually displayed using the CRAN package ggplots2 (53).
Statistics. Differences in OMI index, optical redox ratio, NAD(P)H , FAD , CC3+%, and Ki67+%
between treatment groups were tested using a Wilcoxon rank-sum test. Normalized tumor volumes were compared using a student t-test and a D'agostino-Pearson normality test. Treatment effect size was calculated with Glass's Δ (54).
Results

Organoid generation, drug screening, and optical metabolic imaging
Organoids were generated from fresh patient tissue samples acquired during distal pancreatectomy or pancreaticoduodenectomy (Whipple resection) surgeries. The overall rate of successful organoid formation was 67% (12 of 18 patients) (Fig. 1A) , including mostly pancreatic tumors (pancreatic ductal adenocarcinomas (PDAC) and anaplastic carcinoma of the pancreas), along with two pancreatic intraepithelial neoplasia (PanIN) lesions and one ampullary adenocarcinoma (Supplementary Table S1 ).
50% of the successfully cultured patient samples underwent neoadjuvant treatment prior to resection, including one patient that was downgraded from PDAC to PanIN following a complete pathologic response to chemotherapy (Patient 5). Neoadjuvant treatment did not impede organoid formation (75% and 60% success rates for pretreated and non-pretreated samples respectively). Viability and OMI were validated for pancreatic organoids by quantifying metabolic inhibition to cyanide, a known inhibitor of the electron transport chain ( Supplementary Fig. S1 ). The effects of cyanide on OMI endpoints agreed with previous reports (27) . After an establishment period, organoids were treated with a panel of standard and experimental pancreatic cancer therapies and imaged over a time course (Fig. 1B) . This drug panel included 5-FU and gemcitabine chemotherapy, along with an experimental combination of TAK-228 (mTORC1/2 inhibitor) and ABT-263 (Bcl-2 and Bcl-xL inhibitor). Strategies to inhibit mTOR kinase activity could potentially induce apoptosis (55, 56) , but this process is inhibited by antiapoptotic proteins of the Bcl-2 family (57). Thus, the combination of an mTORC1/2 inhibitor (TAK-228) with a Bcl-2 and Bcl-xL inhibitor (ABT-263) could strongly induce apoptosis in pancreatic cancer. Additional standard drugs were tested on organoids from Patients 6, 13, and 18 at later time points after patient treatment plans were obtained. The length of the organoid establishment period varied by patient between 4 and 12 days (Fig. 1C) , and ended when organoids were clearly visible and proliferating with rounded edges.
Differences in size and cellular quality of patient tumor samples likely contributed to the variance in time to maturation for organoid lines. One line (Patient 6) was thawed after being frozen, requiring additional time to re-establish a usable culture. Representative images demonstrate that multiphoton microscopy measures OMI endpoints with high resolution (Fig. 1D-F) . This allows endpoints to be quantified in individual cells by masking each cell nucleus and cytoplasm using NAD(P)H fluorescence intensity (Fig.   1G ). Tumor cells often grew as 3-dimensional hollow spheres (Fig. 1H ), but other morphologies such as solid spheres were noted. The effects of drugs on the three OMI endpoints at 72 hours is summarized by comparing the mean values across all cells (Fig. 1I-K) . A decrease in the mean optical redox ratio or NAD(P)H (see Equation 2 ), or an increase in the mean FAD is considered an indicator of response to that treatment, based on previous studies in breast organoids (36) . The OMI index combines the complimentary information provided by the three endpoints for each individual cell (Fig. 1L) , and a decrease in the mean OMI index with treatment indicates a metabolic response. At the cellular level, Patient 14 organoids did not respond to 5-FU on average, but did respond to gemcitabine and targeted therapy (all p<0.05 vs. control).
OMI of organoids resolves differential sensitivities to relevant drug treatments
A wide variety of OMI index responses were elicited across treatment conditions and patient samples. In addition to statistical significance of these drug responses, treatment effect sizes were calculated on all OMI measurements in order to determine their magnitude. A heatmap of OMI index treatment effect size, calculated using Glass's Δ at 72 hours post-treatment, shows significant inter-patient heterogeneity for drug response in organoids ( Fig. 2A ; additional drugs and time points in Supplementary   Fig. S2 ). In a subset of patient samples, a significant fibroblast population (co-cultured with organoids) migrated from the 3D matrix and adhered to the 2D glass coverslip. Heterogeneity in these fibroblasts has been shown in organoid models of murine pancreatic cancer (7, 58) . A heatmap of OMI index treatment effect size, calculated using Glass's Δ at 72 hours post-treatment, also shows inter-patient drug response heterogeneity in co-cultured fibroblasts ( Fig. 2B; Supplementary Fig. S3) . Not all drugs were tested on every patient's cells for the full time-course. Drug choices were made based on the availability of viable organoids and the clinical treatment plans (or lack thereof) for individual patients. All organoids were initially treated with the drug panel in Figure 1 because gemcitabine and 5-FU combination therapy was most likely to be prescribed after surgery (excluding Patient 6; it was known in advance that they would receive oxaliplatin rather than gemcitabine). When additional drugs were prescribed for a patient such as nab-paclitaxel or the FOLFIRINOX regimen, their panels were expanded to incorporate those treatments.
Responses to a chemotherapy drug (5-FU) and an experimental targeted therapy combination (TAK-228 and ABT-263) at days 1, 3, and 7 demonstrate how OMI can track single-cell drug responses over time within organoids ( Fig. 2C ; additional drugs and time points in Supplementary Fig. S4 ) and co-cultured fibroblasts ( Fig. 2D; Supplementary Fig. S5 ). For example, response data show an increased response to TAK-228 and ABT-263 combination targeted therapy over time, while 5-FU remained ineffective for most patients.
OMI captures non-genetic cellular heterogeneity in pancreatic organoids
Additional analysis was performed on Patient 13 organoids to evaluate the utility of OMI. The combination of gemcitabine and nab-paclitaxel was used in addition to the standard treatment panel on Patient 13's organoids to mimic the treatment received prior to sample collection (Fig. 3A) . Population density modeling was used to determine whether cellular subpopulations of metabolic response were present in organoids for each treatment condition at 72 hours ( Fig. 3B; Supplementary Fig. S6A ).
Metabolic subpopulations were observed in controls and organoids treated with gemcitabine and nabpaclitaxel (G+P) combination. Patient 13 responded poorly to this treatment prior to surgery and organoid generation. OMI of organoids treated with the experimental combination of TAK-228 and ABT-263 resulted in a single, homogeneous drug-responsive population. Both treatments reduced the degree of heterogeneity present in the organoids, measured with the wH-index, but this reduction was larger with TAK-228 + ABT-263 treatment compared to the standard chemotherapies that the patient received ( Fig.   3C ; additional drugs in Supplementary Fig. S6B ).
High-depth targeted gene sequencing was performed on untreated Patient 13 organoids to determine whether subclonal populations could be resolved to explain the metabolic heterogeneity (Fig.   3D ). A mutation in TP53 tumor-suppressor gene (stop-gain Gln165*) and a mutation in the KRAS oncogene (G12V) were found with allele frequencies of 100% and 52%, respectively, indicating a single Fig. S8 ).
A patient-derived xenograft line was generated and athymic nude mice were treated with combination therapy of gemcitabine and nab-paclitaxel ( Supplementary Fig. S9 ) to determine if in vivo treatment response correlates with that seen in organoids. Tumor growth was tracked by direct caliper measurement and an early reduction was observed over the first 7 days (p<0.05); however, the effect was not sustained.
Heterogeneity of drug response in organoids agrees with later patient recurrence during adjuvant therapy
Seven patients received adjuvant drug treatment following surgical resection of their tumor.
Clinical treatment efficacy was tracked and compared to the OMI prediction of drug response at 72 hours post-treatment in patient-matched organoids. Four patients whose organoids exhibited a homogeneous response to the patient's prescribed therapy were classified as "predicted responders" (Fig. 4) .
Representative redox ratio, NAD(P)H , and FAD images demonstrate the morphological variety as well as a decrease in size or structural integrity with treatment of organoids generated from these patients (1, 2, 6, and 14) (Fig. 4A-D) . Representative images of collapsed organoids that lose their hollow morphology (Fig. 4C,D) , are the result of treatment sensitivity and are generally not present in untreated cultures. Furthermore, the OMI index reflects an organoid response to the prescribed treatment for these patients (p<0.0001) (Fig. 4E-H ). Glass's Δ effect size was calculated for each treatment's OMI index value in addition to statistical significance, and was found to be consistently greater than 0.75 for these patients. Cellular population density modeling of organoids from Patients 1, 2, 6, and 14 did not reveal distinct metabolic subpopulations of response (Fig. 4I-L) . In each case, one homogeneous population of response was found. Fibroblasts co-cultured with organoids from Patients 2 and 14 also showed homogeneous response to the patient's prescribed therapy ( Supplementary Fig. S10 ).
Three patients (3, 8, and 18) whose organoids exhibited treatment response heterogeneity were classified as "predicted non-responders" (Fig. 5) . Representative images show a lack of apparent response in terms of OMI endpoints (Fig. 5A-C Fig. S10 ).
The time between surgical resection and the first evidence of recurrence, or recurrence free survival (RFS) time, was plotted for these seven patients ( with a RFS <12 months (Fig. 6B ). Single-cell OMI distributions in patients with a RFS >12 months were best fit with one subpopulation, while patients with a RFS <12 months were best fit with two (Fig. 6C ).
The degree of heterogeneity, quantified by the wH-index, decreased in treated vs. control organoids in patients with a RFS >12 months, and increased in treated vs. control organoids in patients with a RFS <12 months (Fig. 6D ).
Dimensional reduction of single-cell OMI data reveals organoid cell clustering by patient of origin
UMAP dimensional reduction analysis was performed on the OMI variables of organoid cells
imaged at all time points (45,752 cells) to determine whether cells from different patients exhibited unique metabolic profiles (Fig. 7) . Cells from the same patient generally clustered together (Fig. 7A ). Some patients (e.g. 6, 13, 17) formed a primary cluster and a secondary, smaller cluster. Plotting control and treated cells separately revealed that these secondary clusters occurred due to drug treatment (Fig. 7B,C) .
Discussion
Pancreatic organoids can be used for drug screens directly on patient cells, which could enable rational treatment planning for individual patients (7) (8) (9) . Organoids also provide a platform to discover new drugs and drug combinations to treat pancreatic cancer patients, who currently suffer from a severe lack of effective treatment options. Existing methods to evaluate drug response in organoids ignore cellular heterogeneity, which can lead to patient relapse. Thus, our group developed OMI as a single-cell analysis tool to detect minority subpopulations of drug-resistant cells existing within living organoids that would otherwise appear responsive. We have previously shown that OMI detects subpopulations of drug response in murine PDAC organoids and early treatment responses in human pancreatic organoids (7).
Here, we investigate for the first time whether OMI measurements of early drug response heterogeneity in organoids can capture meaningful treatment responses in individual pancreatic cancer patients.
Organoids were successfully generated from PDAC, precancerous PanIN, anaplastic carcinoma of the pancreas, and ampullary adenocarcinoma tissue samples, with equal success for both pre-treated and treatment-naïve samples. While some time is required to establish healthy organoids for drug screening, OMI measurements began within a 4-12 day window of the patient's surgery. This is crucial for generating individualized treatment plans because pancreatic cancer is often advanced at diagnosis, and any delay to receiving effective therapy may increase mortality. Three independent OMI endpoints (redox ratio, NAD(P)H , and FAD ) were quantified in response to panels of standard drugs (gemcitabine and 5-FU) and experimental targeted therapies that have shown promise in pancreatic cancer (TAK-228 and ABT-263) (Fig. 1) . Each OMI endpoint captures unique metabolic information (27) , and quantitatively combining these three independent measurements into the OMI index provides a technique to evaluate early metabolic response to treatment. An oncologist could use this technology to quickly determine if a patient would benefit from experimental targeted therapies over standard chemotherapies, rather than waiting for standard chemotherapy to fail while exposing the patient to unnecessary toxicities.
OMI was used to track drug response at the single-cell level over a time course of treatment for 11 pancreatic cancer, PanIN, and ampullary cancer patients (Fig. 2) . Time courses are vital to evaluate response, because cells often evolve mechanisms of drug resistance that are not immediately apparent. Our group has shown that OMI non-invasively distinguishes unique groups of cells by their metabolic properties in human breast cancer (36, 38) , human head and neck cancer (37) , and murine PDAC (7). Here, we performed subpopulation analysis on Patient 13 organoid cells to evaluate whether OMI could distinguish cells with distinct drug responses in human pancreatic cancer ( Fig. 3 ; Supplementary Fig. S6 ). Indeed, many treatments caused two distinct subpopulations to form in organoids within 72 hours post-treatment, including the standard chemotherapy regimen given to the patient prior to surgery and organoid generation (gemcitabine with nab-paclitaxel). This suggests that a drug-resistant cell subpopulation persisted throughout the patient's neoadjuvant treatment, and was captured in the organoids. Accordingly, pathology of the patient's resected tumor indicated a poor response to gemcitabine with nab-paclitaxel.
Conversely, targeted therapies induced single populations of homogenous response in Patient 13
organoids. While the combination of gemcitabine and nab-paclitaxel caused a similar average reduction in OMI index as the combination of TAK-228 and ABT-263, the former showed heterogeneity and a drugresistant population, while the latter showed a homogeneous response. This suggests that this targeted therapy combination (TAK-228 and ABT-263) may have been a beneficial alternative for Patient 13. One month after surgery, metastasis in the liver was found on an ultrasound, and the patient died less than two weeks later. This highlights the need for a technology that can rapidly evaluate drug sensitivity in patient cells.
Untreated Patient 13 organoids were also deep-sequenced to determine if genetic heterogeneity could be the source of metabolic subpopulations in untreated organoids. Our metabolic imaging data shows greater heterogeneity than predicted by deep sequencing, as no subclonal populations with pathogenic mutations were found in these organoids. This suggests that the OMI index heterogeneity is likely not genetic in nature, and that OMI is more effective for detecting divergent populations in organoid cultures than destructive sequencing techniques. This work also highlights the importance of metabolic heterogeneity within cancer samples to capture therapeutic response. At 72 hours, a subset of Patient 13 organoids were fixed and stained for proliferation and apoptosis markers. In some cases, OMI detected shifts in metabolism with treatment that had not triggered apoptosis, suggesting that metabolic changes can precede Ki67/CC3 indicators of cell fate, and are an earlier indicator of drug efficacy.
The combination of gemcitabine and nab-paclitaxel was evaluated in vivo in a PDX line established from Patient 13 organoids. A small but transient response in average tumor growth was detected ( Supplementary Fig. S9 ). This poor response is in agreement with the heterogeneous effect found in organoids using OMI. While the PDX model accurately captured the presence of drug resistance in Patient 13's cells, it required months to first establish the PDX line, expand it, and then assess a time course of treatment. While PDX models are an important tool, our studies show that drug screens on organoids can provide more detailed response information with increased cost effectiveness in a clinically meaningful time frame.
OMI of organoids generated from tissues collected at surgery agreed with patient outcome on adjuvant therapy (Fig. 4-6 Finally, we used a dimensionality reduction approach to determine the influence of patient of origin on cellular metabolism in pancreatic organoids (Fig. 7) . control. 
